Healthcare provider profile · identity verified

Sandra Hall-Ross, MD

Internal Medicine · NEW YORK, NY · NPI 1659468742

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	505	173
Amlodipine Besylate	Amlodipine Besylate	459	137
Losartan Potassium	Losartan Potassium	191	63
Levothyroxine Sodium	Levothyroxine Sodium	158	39
Lisinopril	Lisinopril	133	48
Metformin Hcl	Metformin Hcl	132	49
Albuterol Sulfate Hfa	Albuterol Sulfate	121	38
Hydrochlorothiazide	Hydrochlorothiazide	118	35
Metoprolol Succinate	Metoprolol Succinate	114	33
Rosuvastatin Calcium	Rosuvastatin Calcium	100	33
Fluticasone Propionate	Fluticasone Propionate	97	32
Alendronate Sodium	Alendronate Sodium	95	22
Omeprazole	Omeprazole	84	33
Carvedilol	Carvedilol	74	22
Metformin Hcl Er	Metformin Hcl	73	23
Gabapentin	Gabapentin	69	26
Jardiance	Empagliflozin	66	17
Escitalopram Oxalate	Escitalopram Oxalate	64	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	63	22
Pravastatin Sodium	Pravastatin Sodium	62	17
Famotidine	Famotidine	61	18
Ezetimibe	Ezetimibe	57	21
Diclofenac Sodium	Diclofenac Sodium	55	19
Ozempic	Semaglutide	54	16
Montelukast Sodium	Montelukast Sodium	53	17
Pantoprazole Sodium	Pantoprazole Sodium	50	18
Simvastatin	Simvastatin	49	16
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	49	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	47	16
Januvia	Sitagliptin Phosphate	39	11
Valacyclovir	Valacyclovir Hcl	39	14
Breo Ellipta	Fluticasone/Vilanterol	32	suppressed
Incruse Ellipta	Umeclidinium Bromide	31	suppressed
Eliquis	Apixaban	30	13
Atenolol	Atenolol	29	suppressed
Pregabalin	Pregabalin	29	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	27	suppressed
Glimepiride	Glimepiride	26	suppressed
Sertraline Hcl	Sertraline Hcl	26	suppressed
Furosemide	Furosemide	25	suppressed
Meclizine Hcl	Meclizine Hcl	25	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	24	suppressed
Synthroid	Levothyroxine Sodium	23	suppressed
Spironolactone	Spironolactone	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	21	14
Atrovent Hfa	Ipratropium Bromide	20	suppressed
Baclofen	Baclofen	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Ketoconazole	Ketoconazole	19	suppressed
Trazodone Hcl	Trazodone Hcl	19	suppressed
Azelastine Hcl	Azelastine Hcl	18	suppressed
Bupropion Xl	Bupropion Hcl	18	suppressed
Duloxetine Hcl	Duloxetine Hcl	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Ammonium Lactate	Ammonium Lactate	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Allopurinol	Allopurinol	15	suppressed
Finasteride	Finasteride	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Ibandronate Sodium	Ibandronate Sodium	14	suppressed
Ramipril	Ramipril	14	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Clotrimazole	Clotrimazole	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Famciclovir	Famciclovir	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Trulicity	Dulaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error